Harvard Management Company’s Pacific Biosciences PACB Stock Holding History

Harvard Management Company’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-233,186	Closed	-$3.1M	–	28
2023 Q2	$3.1M	Buy	233,186 +4,042	+2%	+$49.1K	0.3%	18
2023 Q1	$2.65M	Hold	229,144	–	–	0.28%	30
2022 Q4	$1.87M	Hold	229,144	–	–	0.23%	33
2022 Q3	$1.33M	Hold	229,144	–	–	0.17%	40
2022 Q2	$1.01M	Hold	229,144	–	–	0.12%	40
2022 Q1	$2.08M	Hold	229,144	–	–	0.21%	37
2021 Q4	$4.69M	Hold	229,144	–	–	0.44%	38
2021 Q3	$5.86M	Buy	+229,144	New	+$6.79M	0.34%	28
2016 Q1	–	Sell	-50,630	Closed	-$665K	–	130
2015 Q4	$665K	Buy	+50,630	New	+$454K	0.06%	95

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Harvard Management Company's PACB Position: Q3 2023 in Review

Harvard Management Company sold out of Pacific Biosciences (PACB) in Q3 2023, closing a stake of 233,186 shares — an estimated $3.1M sold.

Harvard Management Company first reported a position in PACB in Q4 2015 and held it in 9 quarters. The position peaked at $5.86M in Q3 2021. 274 funds tracked by Wall St. Rank hold PACB as of Q3 2023.

Harvard Management Company reported no remaining Pacific Biosciences position as of Q3 2023 after selling out during the quarter.
Harvard Management Company sold 233,186 Pacific Biosciences shares in Q3 2023, an estimated $3.1M.
Harvard Management Company first reported a position in Pacific Biosciences in Q4 2015 and held it in 9 quarters.
Harvard Management Company's Pacific Biosciences position peaked at $5.86M in Q3 2021.
274 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2023.

Based on Harvard Management Company's 13F filing for Q3 2023, filed 9 Nov 2023.